SG11202113297RA - Leader sequence - Google Patents

Leader sequence

Info

Publication number
SG11202113297RA
SG11202113297RA SG11202113297RA SG11202113297RA SG11202113297RA SG 11202113297R A SG11202113297R A SG 11202113297RA SG 11202113297R A SG11202113297R A SG 11202113297RA SG 11202113297R A SG11202113297R A SG 11202113297RA SG 11202113297R A SG11202113297R A SG 11202113297RA
Authority
SG
Singapore
Prior art keywords
leader sequence
leader
sequence
Prior art date
Application number
SG11202113297RA
Other languages
English (en)
Inventor
Nicholas R Waterfield
Joseph Healey
Alexia Hapeshi
Original Assignee
Univ Warwick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Warwick filed Critical Univ Warwick
Publication of SG11202113297RA publication Critical patent/SG11202113297RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
SG11202113297RA 2019-06-07 2020-06-05 Leader sequence SG11202113297RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1908155.3A GB201908155D0 (en) 2019-06-07 2019-06-07 Leader sequence
PCT/GB2020/051380 WO2020245611A1 (en) 2019-06-07 2020-06-05 Leader sequence

Publications (1)

Publication Number Publication Date
SG11202113297RA true SG11202113297RA (en) 2021-12-30

Family

ID=67386182

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202113297RA SG11202113297RA (en) 2019-06-07 2020-06-05 Leader sequence

Country Status (12)

Country Link
US (1) US20230076614A1 (enExample)
EP (1) EP3980545A1 (enExample)
JP (2) JP7748288B2 (enExample)
KR (1) KR20220133757A (enExample)
CN (1) CN114008205A (enExample)
AU (1) AU2020288380A1 (enExample)
BR (1) BR112021024592A2 (enExample)
CA (1) CA3142462A1 (enExample)
GB (1) GB201908155D0 (enExample)
MX (1) MX2021015121A (enExample)
SG (1) SG11202113297RA (enExample)
WO (1) WO2020245611A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4479082A2 (en) * 2022-02-15 2024-12-25 The Broad Institute, Inc. Cell-type specific targeting contractile injection system
AU2023297077A1 (en) 2022-06-30 2025-01-23 Københavns Universitet Contractile injection system and use thereof
CN119735656A (zh) * 2023-09-22 2025-04-01 北京朝赛蕴生物科技有限公司 一种蛋白复合物的制备纯化及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
EP2964240B1 (en) * 2013-03-07 2018-10-24 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides
ES2954940T3 (es) * 2015-10-14 2023-11-27 BASF Agricultural Solutions Seed US LLC Gen de delta-endotoxina axmi554 y procedimientos para su utilización

Also Published As

Publication number Publication date
MX2021015121A (es) 2022-03-17
BR112021024592A2 (pt) 2022-01-18
KR20220133757A (ko) 2022-10-05
JP2022535283A (ja) 2022-08-05
EP3980545A1 (en) 2022-04-13
GB201908155D0 (en) 2019-07-24
JP2025114573A (ja) 2025-08-05
US20230076614A1 (en) 2023-03-09
CN114008205A (zh) 2022-02-01
AU2020288380A1 (en) 2022-01-06
WO2020245611A1 (en) 2020-12-10
CA3142462A1 (en) 2020-12-10
JP7748288B2 (ja) 2025-10-02

Similar Documents

Publication Publication Date Title
CA194148S (en) Camera
CA190078S (en) Case
CA188607S (en) Camera
ZAA201801341S (en) Case
ZAA201801148S (en) Case
PL3810587T3 (pl) Podstawione alkoksypirydynyloindolosulfonoamidy
CA198225S (en) Camera
CA196077S (en) Camera
CA189867S (en) Camera
CA194433S (en) Camera
SG11202113297RA (en) Leader sequence
CA193344S (en) Camera
SMT202300247T1 (it) Inibitori della secrezione proteica a base di triazaciclododecansulfonamide ("tcd")
CA189432S (en) Case
CA189431S (en) Case
PH32018000823S1 (en) Case
PH32018000821S1 (en) Case
PH32018000819S1 (en) Case
PH32018000816S1 (en) Case